Abstract:Background The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50. In this study, we evaluated the efficacy and safety of the combined therapy with terazosin (alpha 1-adrenergic receptor antagonist) and tolterodine (anticholinergic agent) for LUTS associated with BPH. Methods This combination study included 69 patients diagnosed with LUTS associated with BPH based on the International Prostate Symptom Scores (IPSS), urinary flow rate, prostate volume, urinary residual, and their serum prostate-specific antigen levels. Initially, 191 patients were treated with terazosin 2 mg once daily for one week. Those patients with continued LUTS after the initial treatment were allocated randomly into two groups: terazosin group (n=36) in which patients were treated with terazosin 2 mg once daily for six weeks, and combination group (n=33) in which patients were treated with both terazosin 2 mg once daily and tolterodine 2 mg twice daily for 6 weeks. Results The IPSS were significantly improved in both groups after treatment, and the reduction of IPSS in the combination group was significantly greater than that in the terazosin group (P < 0.01). A decrease in urgency, frequency and nocturia were the main contributory factors causing the reduction of IPSS in the combination group. The differences about the peak urinary flow rate and the residual urine from the baseline values were noted in both groups after treatment, but were not significant between the two groups. The incidence of adverse effects in the combination group was higher than that in the terazosin group. As expected the most common adverse effect was mouth dryness which was associated with anticholinergic drugs such as tolterodine. Conclusions Patients with LUTS associated BPH appear the improved IPSS after combined therapy with terazosin and tolterodine. This study, although short term and limited numbers of patients, provides evidence that the combined therapy with terazosin plus tolterodine is a good approach for meeting the objectives of rapid, sustained, and safe improvements in the LUTS associated with BPH. And the profile of patients in this study might be used as the indication of such combined therapy for LUTS associated with BPH without urodynamic evaluation.

Evaluation of the Effectiveness of Terazosin, Tamsulosin a nd Finasteride for Benign Prostatic Hyperplasia

Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.

Evaluation on Safety and Efficacy of Finasteride in Treatment of Benign Prostatic Hyperplasia

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia

Comparison of Different Drugs on the Treatment of Benign Prostate Hyperplasia

Pharmacoeconomic Evaluation of Tamsulosin Hydrochloride Sustained-release Capsules in the Treatment of Benign Prostatic Hyperplasia

Effects of Tamsulosin Combined with Solifenacin on Lower Urinary Tract Symptoms: Evidence from a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials.

A multicenter prospective clinical study on the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia patients

Clinical Comparison of Selective and Non-Selective Alpha 1A-Adrenoceptor Antagonists for Bladder Outlet Obstruction Associated with Benign Prostatic Hyperplasia: Studies on Tamsulosin and Terazosin in Chinese Patients. the Chinese Tamsulosin Study Group.

[Cost and Effectiveness Analysis of Treatments for Benign Prostatic Hyperplasia].

Efficacy and Safety of Combined Therapy with Terazosin and Tolteradine for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: a Prospective Study

Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia

The comparison between finasteride and tamsulosin therapeutic efficacy in the treatment of symptomatic benign prostate hyperplasia

Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis

The efficacy of vardenafil and tamsulosin in treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomised clinical trial

Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia

The Efficacy and Safety of Alpha-1 Blockers for Benign Prostatic Hyperplasia: an Overview of 15 Systematic Reviews

Comparative Effectiveness of Oral Drug Therapies for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: a Systematic Review and Network Meta-Analysis.

The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.